• Analyser helps to Improve Outcomes for Patients on Anti-Platelet Therapy


Analyser helps to Improve Outcomes for Patients on Anti-Platelet Therapy

May 20 2013

Platelet function testing using the Multiplate analyser, now available from Roche, can help to improve outcomes for patients who have had a heart attack or stroke, or who are at risk of bleeding during or after surgery.  Multiplate test results help to predict those who are at increased risk of thrombosis or bleeding and allow anti-platelet tharapy to be tailored to the needs of individual patients.
The addition of Multiplate to Roche’s range of hemostasis analysers further strengthens Roche’s commitment to personalised healthcare by providing powerful companion diagnostics that aid clinical decision-making for hematologists, cardiologists and anesthetists, and help to improve the care of patients with impaired platelet function.
Impaired platelet function can lead to ischemic heart disease and cerebrovascular disease, the two leading causes of death worldwide.  Anti-platelet agents, in particular clopidogrel, are among the most widely used drugs in modern medicine and offer significant improvement in the prevention of thromotic events.  However, 20% of patients do not respond adequately to clopidogrel and are at increased risk of arterial thromboembolism.  Often this is only detected when the patient experiences a secondary thrombotic event.    Other potent, but expensive, anti-platelet agents are now available, such as prasugrel and ticagrelor, which offer advantages and disadvantages over clopidogrel.  It is important to identify which patients respond to clopidogrel so that antiplatelet therapy can be tailored  accordingly and the risk of ischemic and cerebrovascular events reduced.
A recently published consensus recognised Multiplate as the best predictor of ischemic risk compared to other platelet function testing methods.  Multiplate detects both low and high response to clopidogrel, making it ideal to predict the risk of thrombosis, particularly following procedures such as percutaneous coronary intervention (PCI), and to predict the risk of intra- or post-oprative bleeding.  This allows treatment to be tailored immediately, if necessary, to ensure patients are managed safely and effectively.  There is growing evidence that tailoring anti-platelet therapy with Multiplate has the potential to improve outcomes and reduce the incidence of major ischemic complications post PCI.
The Multiplate analyser was acquired during the recent Roche takeover of Verum Diagnostica, an international leader in platelet function testing.